# Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

> **NCT02429258** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 226 (actual)

## Conditions studied

- Type II Diabetes

## Interventions

- **DRUG:** Farxiga
- **DRUG:** Placebo
- **DRUG:** Metformin
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT02429258
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429258, "Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02429258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*